- Home
- LE vs LXEO Comparison
LE vs LXEO Comparison
Compare LE & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- LXEO
- Stock Information
- Founded
- LE 1963
- LXEO 2017
- Country
- LE United States
- LXEO United States
- Employees
- LE N/A
- LXEO N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- LXEO
- Sector
- LE Consumer Discretionary
- LXEO
- Exchange
- LE Nasdaq
- LXEO Nasdaq
- Market Cap
- LE 280.4M
- LXEO 257.0M
- IPO Year
- LE N/A
- LXEO 2023
- Fundamental
- Price
- LE $12.94
- LXEO $4.72
- Analyst Decision
- LE Strong Buy
- LXEO Strong Buy
- Analyst Count
- LE 1
- LXEO 7
- Target Price
- LE $20.00
- LXEO $15.29
- AVG Volume (30 Days)
- LE 390.6K
- LXEO 417.6K
- Earning Date
- LE 09-04-2025
- LXEO 08-14-2025
- Dividend Yield
- LE N/A
- LXEO N/A
- EPS Growth
- LE N/A
- LXEO N/A
- EPS
- LE 0.14
- LXEO N/A
- Revenue
- LE $1,338,672,000.00
- LXEO N/A
- Revenue This Year
- LE $3.31
- LXEO N/A
- Revenue Next Year
- LE $2.34
- LXEO N/A
- P/E Ratio
- LE $95.15
- LXEO N/A
- Revenue Growth
- LE N/A
- LXEO N/A
- 52 Week Low
- LE $7.65
- LXEO $1.45
- 52 Week High
- LE $19.88
- LXEO $12.76
- Technical
- Relative Strength Index (RSI)
- LE 58.02
- LXEO 57.71
- Support Level
- LE $12.60
- LXEO $4.34
- Resistance Level
- LE $13.71
- LXEO $4.99
- Average True Range (ATR)
- LE 0.73
- LXEO 0.37
- MACD
- LE -0.06
- LXEO 0.01
- Stochastic Oscillator
- LE 63.80
- LXEO 67.06
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.